Oncobiologics, Inc. Series B Warrant
ONSIZ
ONSIZ was delisted on the 16th of May, 2018.
12 hedge funds and large institutions have $557K invested in Oncobiologics, Inc. Series B Warrant in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.
20% more funds holding
Funds holding: 10 → 12 (+2)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
56% less capital invested
Capital invested by funds: $1.27M → $557K (-$716K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$4.55K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$2.06K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$533 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$78.2K |
| 2 |
Millennium Management
New York
|
-$321 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $428K | -$78.2K | -429,648 | -46% |
|
|
PA
2
Perceptive Advisors
New York
| $42K | – | – | – |
|
|
CAM
3
Cormorant Asset Management
Boston,
Massachusetts
| $39K | – | – | – |
|
|
ACA
4
Avoro Capital Advisors
New York
| $22K | – | – | – |
|
|
ACP
5
Acuta Capital Partners
Redwood City,
California
| $9K | – | – | – |
|
|
PC
6
PointState Capital
New York
| $9K | – | – | – |
|
|
7
Millennium Management
New York
| $4K | -$321 | -1,761 | -4% |
|
|
MIM
8
Monashee Investment Management
Boston,
Massachusetts
| $2K | +$4.55K | +25,000 | New |
|
9
Morgan Stanley
New York
| $1K | – | – | – |
|
|
VKH
10
Virtu KCG Holdings
New York
| $1K | +$2.06K | +11,304 | New |
|
|
11
UBS Group
Zurich,
Switzerland
| – | +$533 | +2,926 | +260% |
|
ONSIZ Hedge Fund Activity: Q2 2017 in Review
12 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Oncobiologics, Inc. Series B Warrant (ONSIZ) for Q2 2017, worth a combined $557K — down 56% from $1.27M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ONSIZ positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Monashee Investment Management, opening a new position worth an estimated $4.55K. The largest seller was Sabby Management, cutting an estimated $78.2K.
- 12 institutional investors held Oncobiologics, Inc. Series B Warrant (ONSIZ) as of Q2 2017, up from 10 in Q1 2017.
- Funds reported $557K of Oncobiologics, Inc. Series B Warrant stock for Q2 2017, down 56% quarter-over-quarter.
- 2 funds opened new Oncobiologics, Inc. Series B Warrant positions in Q2 2017 and 0 closed out, a net change of +2 holders.
- The largest Oncobiologics, Inc. Series B Warrant buyer in Q2 2017 was Monashee Investment Management, an estimated $4.55K added.
- The largest Oncobiologics, Inc. Series B Warrant seller in Q2 2017 was Sabby Management, an estimated $78.2K sold.
Based on aggregated 13F filings for Q2 2017.